Ye Jing, Chen Er-zhen, Wang Ting-song, Jiang Jie, Li Xiao-guang, Li Yang, Yang Zhi-tao, Lu Yi-ming
Emergency Department of Ruijin Hospital Affiliated to School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China.
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2008 Sep;20(9):538-41.
To determine the clinical significance of serum myoglobin (Mb) in the evaluation of severity and prognosis of non-cardiogenic critically ill patients by comparing with acute physiology and chronic health evaluation II (APACHE II) score.
One hundred and thirty patients admitted consecutively to emergency intensive care unit (EICU) from April to December in 2005 were enrolled for the study. Determination of serum Mb content, routine serum biochemical tests and APACHE II scoring were performed simultaneously. The serum Mb was measured with the use of chemoluminescence and solid-chromatography. All the patients were followed up till recovery/discharge or death.
APACHE II score, white blood cell count and mortality were significantly different between the two groups classified by the content of serum Mb [Mb < 140 microg/L (76 patients) and Mb > or = 140 microg/L (55 patients)]. When Mb rose, diseases aggravated, APACHE II score and mortality went up (both P < 0.01). APACHE II score, Mb and neutrophil were remarkably higher in the death group (45 patients) than the recovery group (86 patients, all P < 0.01). Stepwise Cox Regression showed that Mb and APACHE II score were the parameters that related to the survival rate, while Mb was the main option. When Mb > 500 microg/L, the mortality rate was 82% (23/28); when APACHE II score > 20, the mortality rate was 85% (23/27); the morality rate went up to 95% (19/20) in the patients with Mb > 500 microg/L and APACHE II score > 20, suggesting that a combination of Mb determination and APACHE II score would raise the accuracy of evaluation of the prognosis of critically ill patients.
Compares with APACHE II score for evaluation of critical illness, Mb can also be considered as a significant biomarker to evaluate the seriousness of the ailment in the critically ill and to judge the effect of the treatment.Therefore, it could be used as a prospective and meaningful biomarker for a quick evaluation of the disease severity in the ICU, so it is worth for further study.
通过与急性生理与慢性健康状况评分系统II(APACHE II)评分比较,探讨血清肌红蛋白(Mb)在评估非心源性危重症患者病情严重程度及预后中的临床意义。
选取2005年4月至12月连续入住急诊重症监护病房(EICU)的130例患者作为研究对象。同时测定血清Mb含量、常规血清生化指标并进行APACHE II评分。采用化学发光法和固相色谱法测定血清Mb。所有患者随访至康复/出院或死亡。
根据血清Mb含量[Mb<140μg/L(76例)和Mb≥140μg/L(55例)]分为两组,两组患者的APACHE II评分、白细胞计数及死亡率差异有统计学意义。随着Mb升高,病情加重,APACHE II评分及死亡率升高(均P<0.01)。死亡组(45例)的APACHE II评分、Mb及中性粒细胞均显著高于康复组(86例,均P<0.01)。逐步Cox回归分析显示,Mb和APACHE II评分是与生存率相关的参数,其中Mb是主要因素。当Mb>500μg/L时,死亡率为82%(23/28);当APACHE II评分>20时,死亡率为85%(23/27);当Mb>500μg/L且APACHE II评分>20时,死亡率高达95%(19/20),提示联合检测Mb和APACHE II评分可提高危重症患者预后评估的准确性。
与APACHE II评分相比,Mb也可作为评估危重症患者病情严重程度及判断治疗效果的重要生物标志物。因此,其可作为一种有前景且有意义的生物标志物用于快速评估ICU患者的疾病严重程度,值得进一步研究。